Eda Eylemer Mocan
Overview
Explore the profile of Eda Eylemer Mocan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
19
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yalciner M, Yazgan S, Mocan E, Karaoglan B, Bolek H, Yekeduz E, et al.
Clin Transl Oncol
. 2025 Jan;
PMID: 39873944
Purpose: Immunotherapy efficacy in elderly patients with comorbidities and poor performance status is not well understood. More knowledge on this topic is needed to identify subgroups that will benefit from...
2.
Kahraman S, Hizal M, Demirel B, Guven D, Gumusay O, Uluc B, et al.
BMC Cancer
. 2024 Dec;
24(1):1592.
PMID: 39736618
Highly selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6is) have emerged as a standart of care for first- and second-line therapies in combination with endocrine therapy (ET) for HR+/HER2-...
3.
On S, Koksal B, Arik Z, Caner B, Ercan Uzundal D, Yazici O, et al.
Curr Oncol
. 2024 Nov;
31(11):6803-6813.
PMID: 39590133
(1) Background: Metastatic L-type sarcomas (liposarcoma and leiomyosarcoma) are rare and have a poor prognosis. Trabectedin is an effective agent that can be used after anthracyclines. This study was designed...
4.
Karaoglan B, Yekeduz E, Yazgan S, Mocan E, Koksoy E, Yasar H, et al.
Immunotherapy
. 2024 Jul;
16(12):821-828.
PMID: 39016058
Low serum sodium affects cancer prognosis, but its impact on immunotherapy is unclear. Assessing the association of pre- and post-ICI treatment sodium levels with survival. We retrospectively analyzed patients receiving...
5.
Arak H, Erkilic S, Yaslikaya S, Mocan E, Aktas G, Ozdemir M, et al.
J Immunother
. 2024 Feb;
47(5):182-189.
PMID: 38333962
Our aim was to assess the efficacy of adjuvant programmed cell death protein-1 (PD-1) inhibitors and compare the other adjuvant treatments in patients with surgically resected stage III or IV...
6.
Mocan E, Yekeduz E, Karatas G, Yazgan S, Koksoy E, Senler F, et al.
Anticancer Drugs
. 2023 Nov;
35(2):190-194.
PMID: 38018837
Histamine and H1 receptors play a crucial role in the tumor microenvironment. Preclinical data showed that concomitant use of antihistamines and immune checkpoint inhibitors (ICIs) might increase the effect of...
7.
Kahraman S, Erul E, Seyyar M, Gumusay O, Bayram E, Demirel B, et al.
Future Oncol
. 2023 May;
19(10):727-736.
PMID: 37133230
Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The authors report retrospective...
8.
Karacin C, Oksuzoglu B, Demirci A, Keskinkilic M, Baytemur N, Yilmaz F, et al.
BMC Cancer
. 2023 Feb;
23(1):192.
PMID: 36849943
No abstract available.
9.
Karacin C, Oksuzoglu B, Demirci A, Keskinkilic M, Baytemur N, Yilmaz F, et al.
BMC Cancer
. 2023 Feb;
23(1):136.
PMID: 36765293
Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which...